Drug Search Results
More Filters [+]

BR-55

Alternative Names: br-55, br55, br 55
Latest Update: 2024-09-19
Latest Update Note: Clinical Trial Update

Product Description

BR55, an ultrasound contrast agent functionalized with a heterodimer peptide targeting the vascular endothelial growth factor receptor 2 (VEGFR2), was evaluated in vitro and in vivo, demonstrating its potential for specific tumor detection.

Mechanisms of Action: Imaging Agent,VEGFR2

Novel Mechanism: Yes

Modality: Diagnostic Agent

Route of Administration: Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Bracco Imaging
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BR-55

Countries in Clinic: China

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Breast Diseases|Inflammatory Breast Cancer|Ovarian Cancer|Ovarian Diseases|Thyroid Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CTR20220634

P2

Not yet recruiting

Breast Diseases|Inflammatory Breast Cancer|Ovarian Cancer|Thyroid Cancer|Ovarian Diseases

None

Recent News Events